Skip to main content

Blue Star Infotech Ltd Rs 286/: Breaking News

Blue Star Infotech Ltd (BSIL) , part of Blue Star group, offers solftware solutions in Digital Transformation and Software Product Engineering with operations in UDA, UK, Europe, Malaysia and Singapore. Company is focused on delivering valued-added and future-proofed software solutions by leveraging emerging technologies and trends while preserving existing investments for gaining competitive advantages. BSIL caters to the IT and software R&D needs of enterprises globally and offers a broad spectrum of services ranging from Application Development and Management, Product engineering, Package Implementation and Testing to emerging areas such as Business Intelligence/Analytics, Mobility and Cloud Computing. Its technology labs for Mobility, Cloud Computing, Analytics and Usability engineering incubate and propagate new methodologies, standards, tools and solutions.

BSIL has been delivering consistently good financials:

                                 Q  U   A   R   T    E   R     E  N   D   E   D          Y/ENDED
                                 30.6.2015             31.3.2015         30.6.2014            31.3.2015
                                  Rs/Cr                  Rs/Cr                Rs/Cr                Rs/Cr

Total Income               74.29                 69.63                 64.46               264.88

PBT                           10.23                   6.62                    4.04                25.49

PAT                             7.26                  4.67                    3.10                18.16

Equity                                                                            10.39                10.80

EpsRs                         6.73                  4.32                      2.99                17.18

For FY15, BSIL had reported revenue of 264.88 crores out of which exports (overseas revenues) were 235.45 crores. It means co is deriving nearly 90% of its revenues from overseas clients. Eps for FY15 stood at Rs 17.18.

For Q1/FY16, BSIL has achieved revenue of Rs 74.29 crores , growth of 15.2% YoY basis. However, PAT has flared up YoY 134% to 7.26 crores, translating into Eps of Rs 6.73. During the quarter, co has procured a big order worth Rs 96 crores and such steep rise in profits has been possible due to closing of unremunerative business, streamlining internal processes and result of past rationalisations.  BSIL can report Eps of Rs 24-26 for FY16.  Weakening rupees should enhance its earnings further as major revenues are from overseas clients.Stock is trading at just 12xFY16Eeps.

BREAKING NEWS:  It is reliably learnt that PROMOTERS HAVE DECIDED TO SELL THEIR ENTIRE 51% stake to a foreign co (name of buyer not being disclosed here) @ Rs 380 per share. Announcement in this regard can be expected in next 2-4 weeks.

In immediate short term, stock should rise to Rs 350-360. However, under new management of overseas buyers, BSIL can and should witness big increase in its revenues and profits in next 12-36 months. Investors may remember that how Kale Consultants  has delivered huge appreciation to its investors within 2-3 years of acquisition by foreign co. We estimate that similar transformation should happen with Blue Star Infotech also. Hence, if investors hold on to Blue Star Info for 2 years, stock may rise to Rs 750+

Comments

Post a Comment

Popular posts from this blog

Best Buy For Monday Upper Circuit Expected TCI FINANCE

*Intraday & Short Term News For Monday* *Fii And Dii News*   *TCI FINANCE LTD (501242 & NSE) (31)*   Incorporated in 1973, TCI Finance Ltd (TCIFL) is a Non-Banking Finance Company (NBFC) registered with the RBI and engaged in the business of Inter-Corporate Deposits, investment in equities of bodies corporate etc.   The Company was promoted by Mr. Mahendra Agarwal, who is also the Managing Director and CEO of Gati Ltd, a pioneer in express distribution and supply chain and promoted by TCFIL   The Rs.2 paid-up share of Gati Ltd currently trades at Rs.113. TCIFL has one subsidiary - ITAG Business Solutions Ltd engaged in the business of Knowledge Process Outsourcing (KPO) in the domain of Intellectual Property Services.   *It is co-promoter of GATI LTD. Company is holding 55,12,455 shares (5.09%) stake in GATI LTD. At CMP value of investments is around Rs.62.3crore. Equity is Rs.12.87crore. Thus value of investment works out to Rs.48.4 per share ...
1 comment
Read more

Danlaw Technologies India Ltd: For multi-bagger gains (BSE Code: 532329) (CMP: Rs. 60.75) (FV: Rs.10)

The earnings season so far has been weak and worries over domestic growth continue to weigh on the market sentiment which has led the markets back on the downward path.. A value investor, however, need not worry about the broad markets as value stocks perform better and post good results. One such value-pick is Danlaw Technologies India Ltd. (DTIL). Company background: DTIL is the offshore technology and product development center of its parent company - Danlaw Incorporated, founded by Mr. Raju Dandu and Mr. Lloyd Lawrence in Michigan, USA in 1984. DTIL’s mission is to provide high quality services and products in Automotive Electronics, develop R&D driven Signal Processing technologies for communication and control, configure solutions and provide exceptional Information Technology (IT) services in the areas of education, health, banking and e-governance and provide world-class products and solutions for secured access through biometric access control technologies with intellige...
1 comment
Read more

Some Opportunities Are left in Pharma Sector

Torrent Pharmaceuticals  reported impressive 75% growth in revenues and profit in the first quarter of FY 2016. The sterling performance was driven by the launch of new product in the US market, which has limited competition at present. The focus is on the therapeutic segments of cardiovascular and CNS. There is presence in gastro-intestinal, diabetology, anti-infective, pain management, nephrology, oncology, gynecology and pediatric segments as well. The manufacturing plants for formulations and bulk drugs have been approved by authorities of several regulated and semi-regulated markets such as the US, the UK, Brazil, Germany, Australia and South Africa. Capacity will increase almost 100% once the new plant at Dahej in Gujarat becomes operational. The plant will be one of the largest pharmaceuticals manufacturing facilities in the country at a single location. The unit will primarily cater to the key regulated markets of the US and Europe. Approval from regulators such...
Post a Comment
Read more